1. Home
  2. PBLS vs BATRK Comparison

PBLS vs BATRK Comparison

Compare PBLS & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$31.28

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Logo Atlanta Braves Holdings Inc. Series C

BATRK

Atlanta Braves Holdings Inc. Series C

HOLD

Current Price

$50.28

Market Cap

3.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBLS
BATRK
Founded
N/A
1991
Country
United States
United States
Employees
N/A
1610
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.3B
IPO Year
2026
N/A

Fundamental Metrics

Financial Performance
Metric
PBLS
BATRK
Price
$31.28
$50.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$60.00
AVG Volume (30 Days)
502.7K
554.3K
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.40
Revenue Next Year
N/A
$8.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.56
$37.76
52 Week High
$33.65
$53.25

Technical Indicators

Market Signals
Indicator
PBLS
BATRK
Relative Strength Index (RSI) 56.52 45.40
Support Level $26.83 $50.28
Resistance Level $33.65 $52.74
Average True Range (ATR) 2.62 1.15
MACD 0.14 -0.29
Stochastic Oscillator 63.76 28.43

Price Performance

Historical Comparison
PBLS
BATRK

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: